Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment
|ClinicalTrials.gov Identifier: NCT01145144|
Recruitment Status : Completed
First Posted : June 16, 2010
Last Update Posted : June 16, 2010
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Stimulation||Drug: dehydroepiandrosterone crystalline fine powder||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||January 2008|
|Actual Primary Completion Date :||July 2009|
|Actual Study Completion Date :||July 2009|
Experimental: DHEA supplementation
DHEA was added to induction of ovulation by recombinant FSH and recombinant LH, in IVF long protocol
|Drug: dehydroepiandrosterone crystalline fine powder|
|No Intervention: only induction of ovulation by same long protocol without DHEA|
- peak estradiol level.
- number of retrieved oocytes.
- Embryos that were graded as a top quality (according to the number of cells and percent of fragmentation)
- number of embryos reserved for transfer.
- pregnancy rate.
- live birth rate.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01145144
|Meir Medical center IVF unit|
|kfar Saba, Israel|
|Meir Medical Center|
|Kfar Sava, Israel|